Transaction DateRecipientSharesTypePriceValue
17th August 2020Sachs Group Inc Goldman1,500,000Open or private sale$27.50$41,250,000.00
17th August 2020Sachs Group Inc Goldman225,000Open or private sale$27.50$6,187,500.00
27th May 2020Sachs Group Inc Goldman6,420Grant/award etc.$0.00
1st April 2020Sachs Group Inc Goldman376Open or private purchase$9.41$3,538.16
1st April 2020Sachs Group Inc Goldman300Open or private purchase$9.25$2,775.00
25th March 2020Sachs Group Inc Goldman200Open or private sale$46.75$9,350.00
25th March 2020Sachs Group Inc Goldman100Open or private sale$48.10$4,810.00
25th March 2020Sachs Group Inc Goldman100Open or private sale$47.02$4,702.00
25th March 2020Sachs Group Inc Goldman200Open or private sale$48.13$9,626.00
25th March 2020Sachs Group Inc Goldman1Open or private sale$48.44$48.44
T2 Biosystems
T2 Biosystems logo

T2 Biosystems, Inc. engages in the development of proprietary technology platform. It offers the T2 Magnetic Resonance technology which enables rapid detection of pathogens, biomarkers and other abnormalities.

Ticker: TTOO
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1492674
Employees: 151
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $27 M (0%)
Marketable Securities, Current: $9 M (0%)
Inventory, Net: $4 M (0%)
Assets, Current: $47 M (150%)
Property, Plant and Equipment, Net: $4 M (0%)
Other Assets, Noncurrent: $206 Th (0%)
Assets: $54 M (88%)
Accounts Payable, Current: $2 M (-52%)
Accrued Liabilities, Current: $6 M (0%)
Liabilities, Current: $8 M (-86%)
Common Stock, Value, Issued: $128 Th (150%)
Common Stock, Shares, Issued: $128 M (153%)
Additional Paid in Capital, Common Stock: $397 M (16%)
Retained Earnings (Accumulated Deficit): $402 M (0%)
Stockholders' Equity (Parent): $4 M (0%)
Liabilities and Equity: $54 M (88%)
Revenue: $3 M (0%)
Research and Development: $4 M (-55%)
Operating Income/Loss: $9 M (-60%)